The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Open accessAbstract
BACKGROUND: Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive pulmonary disease (COPD) and repeated exacerbations. They are commonly used as combination inhalers with long-acting beta2-agonists (LABA) to reduce exacerbation rates and all-cause mortality, and to improve lung function and quality of life. The most common combinations of ICS and LABA used in combination inhalers are fluticasone and salmeterol, budesonide and formoterol and a new formulation of fluticasone in combination with vilanterol, which is now available. ICS have been associated with increased risk of pneumonia, but the magnitude of risk and how this compares with different ICS remain unclear. Recent reviews conducted to address their safety have not compared the relative safety of these two drugs when used alone or in combination with LABA. OBJECTIVES: To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD. SEARCH METHODS: We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), clinicaltrials.gov, reference lists of existing systematic reviews and manufacturer websites. The most recent searches were conducted in September 2013. SELECTION CRITERIA: We included parallel-group randomised controlled trials (RCTs) of at least 12 weeks' duration. Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted study characteristics, numerical data and risk of bias information for each included study.We looked at direct comparisons of ICS versus placebo separately from comparisons of ICS/LABA versus LABA for all outcomes, and we combined these with subgroups when no important heterogeneity was noted. After assessing for transitivity, we conducted an indirect comparison to compare budesonide versus fluticasone monotherapy, but we could not do the same for the combination therapies because of systematic differences between the budesonide and fluticasone combination data sets.When appropriate, we explored the effects of ICS dose, duration of ICS therapy and baseline severity on the primary outcome. Findings of all outcomes are presented in 'Summary of findings' tables using GRADEPro. MAIN RESULTS: We found 43 studies that met the inclusion criteria, and more evidence was provided for fluticasone (26 studies; n = 21,247) than for budesonide (17 studies; n = 10,150). Evidence from the budesonide studies was more inconsistent and less precise, and the studies were shorter. The populations within studies were more often male with a mean age of around 63, mean pack-years smoked over 40 and mean predicted forced expiratory volume of one second (FEV1) less than 50%.High or uneven dropout was considered a high risk of bias in almost 40% of the trials, but conclusions for the primary outcome did not change when the trials at high risk of bias were removed in a sensitivity analysis.Fluticasone increased non-fatal serious adverse pneumonia events (requiring hospital admission) (odds ratio (OR) 1.78, 95% confidence interval (CI) 1.50 to 2.12; 18 more per 1000 treated over 18 months; high quality), and no evidence suggested that this outcome was reduced by delivering it in combination with salmeterol or vilanterol (subgroup differences: I(2) = 0%, P value 0.51), or that different doses, trial duration or baseline severity significantly affected the estimate. Budesonide also increased non-fatal serious adverse pneumonia events compared with placebo, but the effect was less precise and was based on shorter trials (OR 1.62, 95% CI 1.00 to 2.62; six more per 1000 treated over nine months; moderate quality). Some of the variation in the budesonide data could be explained by a significant difference between the two commonly used doses: 640 mcg was associated with a larger effect than 320 mcg relative to placebo (subgroup differences: I(2) = 74%, P value 0.05).An indirect comparison of budesonide versus fluticasone monotherapy revealed no significant differences with respect to serious adverse events (pneumonia-related or all-cause) or mortality. The risk of any pneumonia event (i.e. less serious cases treated in the community) was higher with fluticasone than with budesonide (OR 1.86, 95% CI 1.04 to 3.34); this was the only significant difference reported between the two drugs. However, this finding should be interpreted with caution because of possible differences in the assignment of pneumonia diagnosis, and because no trials directly compared the two drugs.No significant difference in overall mortality rates was observed between either of the inhaled steroids and the control interventions (both high-quality evidence), and pneumonia-related deaths were too rare to permit conclusions to be drawn. AUTHORS' C
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Fit Yourself and Take Your Lungs to Heart
Palange, P., & Bonini, M. (2013) · Respiration · doi:10.1159/000350831 · Cited by 2,779
Pulmonary rehabilitation for chronic obstructive pulmonary disease
McCarthy, B., Casey, D., Devane, D., Murphy, K., Murphy, E., & Lacasse, Y. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003793.pub3 · Cited by 2,643
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Musher, D. M., & Fine, M. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313954 · Cited by 2,286
Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00049-8 · Cited by 2,052
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
Lim, W. S., Baudouin, S. V., George, R. C., Hill, A. T., Jamieson, C., Le Jeune, I., Macfarlane, J. T., Read, R. C., Roberts, H. J., Levy, M. L., et al. (2009) · Thorax · doi:10.1136/thx.2009.121434 · Cited by 1,420
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Pauwels, R. A., Löfdahl, C.-G., Laitinen, L. A., Schouten, J. P., Postma, D. S., Pride, N. B., & Ohlsson, S. V. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402503 · Cited by 1,074
Conceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
Puhan, M. A., Gimeno-Santos, E., Cates, C. J., & Troosters, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005305.pub4 · Cited by 991
Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00031402 · Cited by 887
(2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432601 · Cited by 830
Pulmonary rehabilitation for chronic obstructive pulmonary disease
Lacasse, Y., Goldstein, R., Lasserson, T. J., & Martin, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003793.pub2 · Cited by 821
Vestbo, J., Søorensen, T., Lange, P., Brix, A., Torre, P., & Viskum, K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10019-3 · Cited by 816
Celli, B. R., Thomas, N. E., Anderson, J. A., Ferguson, G. T., Jenkins, C. R., Jones, P. W., Vestbo, J., Knobil, K., Yates, J. C., & Calverley, P. M. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1869oc · Cited by 748
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Calverley, P. M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027003 · Cited by 730
Indirect comparisons of competing interventions
Glenny, A., Altman, D., Song, F., Sakarovitch, C., Deeks, J., D'Amico, R., Bradburn, M., & Eastwood, A. (2005) · Health Technology Assessment · doi:10.3310/hta9260 · Cited by 677
McGarvey, L. P., John, M., Anderson, J. A., Zvarich, M., & Wise, R. A. (2007) · Thorax · doi:10.1136/thx.2006.072348 · Cited by 561
Self-management education for patients with chronic obstructive pulmonary disease
Effing, T., Monninkhof, E. E., van der Valk, P. P. D. L. P. M., Zielhuis, G. G., Walters, E. H., van der Palen, J. J., & Zwerink, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002990.pub2 · Cited by 536
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Yang, I. A., Clarke, M. S., Sim, E. H., & Fong, K. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002991.pub3 · Cited by 523
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
Calverley, P. M. A. (2003) · Thorax · doi:10.1136/thorax.58.8.659 · Cited by 512
Paggiaro, P. L., Dahle, R., Bakran, I., Frith, L., Hollingworth, K., & Efthimiou, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)03471-5 · Cited by 508
Mahler, D. A., Wire, P., Horstman, D., Chang, C.-N., Yates, J., Fischer, T., & Shah, T. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2112055 · Cited by 495
Inhaled corticosteroids in COPD and the risk of serious pneumonia
Suissa, S., Patenaude, V., Lapi, F., & Ernst, P. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202872 · Cited by 444
Impact of preventing exacerbations on deterioration of health status in COPD
Spencer, S., Calverley, P. M. A., Burge, P. S., & Jones, P. W. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00121404 · Cited by 441
Ernst, P., Gonzalez, A. V., Brassard, P., & Suissa, S. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200611-1630oc · Cited by 389
Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease
Puhan, M. A., Gimeno-Santos, E., Scharplatz, M., Troosters, T., Walters, E. H., & Steurer, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005305.pub3 · Cited by 379
Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J., & Fan, E. (2008) · JAMA · doi:10.1001/jama.2008.717 · Cited by 364
Singh, S., Amin, A. V., & Loke, Y. K. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.550 · Cited by 346
Jenkins, C. R., Jones, P. W., Calverley, P. M., Celli, B., Anderson, J. A., Ferguson, G. T., Yates, J. C., Willits, L. R., & Vestbo, J. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-59 · Cited by 345
Dransfield, M. T., Bourbeau, J., Jones, P. W., Hanania, N. A., Mahler, D. A., Vestbo, J., Wachtel, A., Martinez, F. J., Barnhart, F., Sanford, L., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70040-7 · Cited by 345
Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease
SPENCER, S., CALVERLEY, P. M. A., SHERWOOD BURGE, P., & JONES, P. W. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.1.2005009 · Cited by 334
Hanania, N. A., Darken, P., Horstman, D., Reisner, C., Lee, B., Davis, S., & Shah, T. (2003) · Chest · doi:10.1378/chest.124.3.834 · Cited by 327
Kardos, P., Wencker, M., Glaab, T., & Vogelmeier, C. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-244oc · Cited by 314
van der Valk, P., Monninkhof, E., van der Palen, J., Zielhuis, G., & van Herwaarden, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-512oc · Cited by 298
Nannini, L. J., Poole, P., Milan, S. J., Holmes, R., & Normansell, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub4 · Cited by 274
Hattotuwa, K. L., Gizycki, M. J., Ansari, T. W., Jeffery, P. K., & Barnes, N. C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2105025 · Cited by 270
Prevalence and Progression of Osteoporosis in Patients With COPD
Ferguson, G. T., Calverley, P. M. A., Anderson, J. A., Jenkins, C. R., Jones, P. W., Willits, L. R., Yates, J. C., Vestbo, J., & Celli, B. (2009) · Chest · doi:10.1378/chest.08-3016 · Cited by 265
Nannini, L. J., Lasserson, T. J., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006829.pub2 · Cited by 264
Jones, P. W., Willits, L. R., Burge, P. S., & Calverley, P. M. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00013303 · Cited by 249
Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study
Jenkins, C. R., Celli, B., Anderson, J. A., Ferguson, G. T., Jones, P. W., Vestbo, J., Yates, J. C., & Calverley, P. M. A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00194610 · Cited by 235
Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations
Ferguson, G. T., Anzueto, A., Fei, R., Emmett, A., Knobil, K., & Kalberg, C. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.04.019 · Cited by 232
The TORCH (TOwards a Revolution in COPD Health) survival study protocol: Fig. 1.—
The TORCH Study Group (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00120603 · Cited by 224
Pauwels, R., Lofdahl, C., Pride, N., Postma, D., Laitinen, L., & Ohlsson, S. (1992) · European Respiratory Journal · doi:10.1183/09031936.93.05101254 · Cited by 217
Cardiovascular events in patients with COPD: TORCH Study results
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Crim, C., Willits, L. R., Yates, J. C., Vestbo, J., et al. (2010) · Thorax · doi:10.1136/thx.2010.136077 · Cited by 207
Tashkin, D. P., Rennard, S. I., Martin, P., Ramachandran, S., Martin, U. J., Silkoff, P. E., & Goldman, M. (2008) · Drugs · doi:10.2165/00003495-200868140-00004 · Cited by 202
Budesonide and the risk of pneumonia: a meta-analysis of individual patient data
Sin, D. D., Tashkin, D., Zhang, X., Radner, F., Sjöbring, U., Thorén, A., Calverley, P. M., & Rennard, S. I. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61250-2 · Cited by 201
Song, F., Harvey, I., & Lilford, R. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.06.006 · Cited by 195
Lapperre, T. S., Snoeck-Stroband, J. B., Gosman, M. M. E., Jansen, D. F., van Schadewijk, A., Thiadens, H. A., Vonk, J. M., Boezen, H. M., ten Hacken, N. H. T., Sont, J. K., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-8-200910200-00004 · Cited by 189
Celli, B., Vestbo, J., Jenkins, C. R., Jones, P. W., Ferguson, G. T., Calverley, P. M. A., Yates, J. C., Anderson, J. A., Willits, L. R., & Wise, R. A. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201004-0665oc · Cited by 186
Rennard, S. I., Tashkin, D. P., McElhattan, J., Goldman, M., Ramachandran, S., Martin, U. J., & Silkoff, P. E. (2009) · Drugs · doi:10.2165/00003495-200969050-00004 · Cited by 185
Janson, C., Larsson, K., Lisspers, K. H., Stallberg, B., Stratelis, G., Goike, H., Jorgensen, L., & Johansson, G. (2013) · BMJ · doi:10.1136/bmj.f3306 · Cited by 177
Effects of Long-term Treatment With Corticosteroids in COPD
Renkema, T. E., Schouten, J. P., Koëter, G. H., & Postma, D. S. (1996) · Chest · doi:10.1378/chest.109.5.1156 · Cited by 176
Anzueto, A., Ferguson, G. T., Feldman, G., Chinsky, K., Seibert, A., Emmett, A., Knobil, K., O'Dell, D., Kalberg, C., & Crater, G. (2009) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550903140881 · Cited by 172
van Grunsven, P. M., van Schayck, C. P., Derenne, J. P., Kerstjens, H. A. M., Renkema, T. E. J., Postma, D. S., Similowski, T., Akkermans, R. P., Jong, P. C. M. P.-D., Dekhuijzen, P. N. R., et al. (1999) · Thorax · doi:10.1136/thx.54.1.7 · Cited by 167
Smoking cessation for chronic obstructive pulmonary disease
van der Meer, R. M., Wagena, E. J., Ostelo, R., Jacobs, A., & van Schayck, O. C. P. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002999 · Cited by 162
Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study
Sharafkhaneh, A., Southard, J. G., Goldman, M., Uryniak, T., & Martin, U. J. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2011.07.020 · Cited by 160
Jarad, N. A., Wedzicha, J. A., Burge, P. S., & Calverley, P. M. A. (1999) · Respiratory Medicine · doi:10.1016/s0954-6111(99)90001-x · Cited by 160
Inhaled corticosteroids for stable chronic obstructive pulmonary disease
Yang, I. A., Fong, K. M., Sim, E., Black, P., & Lasserson, T. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002991.pub2 · Cited by 153
Burge, P. S. (2003) · Thorax · doi:10.1136/thorax.58.8.654 · Cited by 153
Bourbeau, J., Christodoulopoulos, P., Maltais, F., Yamauchi, Y., Olivenstein, R., & Hamid, Q. A. (2007) · Thorax · doi:10.1136/thx.2006.071068 · Cited by 149
Spencer, M., Briggs, A. H., Grossman, R. F., & Rance, L. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523060-00008 · Cited by 132
Development of fluticasone propionate and comparison with other inhaled corticosteroids
Johnson, M. W. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70155-1 · Cited by 129
Martínez, F. J., Boscia, J., Feldman, G., Scott-Wilson, C. A., Kilbride, S., Fabbri, L. M., Crim, C. C., & Calverley, P. M. A. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2012.12.016 · Cited by 125
Bourbeau, J., Rouleau, M.-È., & Boucher, S. (1998) · Thorax · doi:10.1136/thx.53.6.477 · Cited by 120
Johnell, O., Pauwels, R., Lofdahl, C., Laitinen, L. A., Postma, D. S., Pride, N. B., & Ohlsson, S. V. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00276602 · Cited by 112
Withdrawal From Treatment as an Outcome in the ISOLDE Study of COPD
Calverley, P. M. A., Spencer, S., Willits, L. R., Burge, P. S., & Jones, P. (2003) · CHEST Journal · doi:10.1378/chest.124.4.1350 · Cited by 108
Holland, W. W. (1993) · Journal of Epidemiology & Community Health · doi:10.1136/jech.47.1.4 · Cited by 108
The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol
Vestbo, J., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Crim, C. C., Haumann, B., Martínez, F. J., Yates, J., & Newby, D. E. (2012) · European Respiratory Journal · doi:10.1183/09031936.00087312 · Cited by 105
Relationship between respiratory symptoms and medical treatment in exacerbations of COPD
Calverley, P. M. A., Pauwels, R., Lofdahl, C., Svensson, K., Higenbottam, T., Carlsson, L., & Ståhl, E. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00143404 · Cited by 103
A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD
Kerwin, E., Scott-Wilson, C. A., Sanford, L., Rennard, S. I., Agustí, A. G. N., Barnes, N. C., & Crim, C. C. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2012.12.014 · Cited by 101
Beclomethasone/formoterol in the management of COPD: A randomised controlled trial
Calverley, P. M. A., Kuna, P., Monsó, E., Costantini, M., Petruzzelli, S., Sergio, F., Varoli, G., Papi, A. A., & Brusasco, V. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.09.008 · Cited by 101
Yawn, B. P., Li, Tian, T., Zhang, Arcona, S., & Kähler (2013) · International Journal of COPD · doi:10.2147/copd.s42366 · Cited by 92
Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study
Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., Yates, J., & Jones, P. (2010) · The Clinical Respiratory Journal · doi:10.1111/j.1752-699x.2010.00198.x · Cited by 86
Kunz, L. I. Z., Strebus, J., Budulac, S. E., Lapperre, T. S., Sterk, P. J., Postma, D. S., Mauad, T., Timens, W., Hiemstra, P. S., & the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0063430 · Cited by 83
Choudhury, A. B., Dawson, C. M., Kilvington, H. E., Eldridge, S. M., James, W.-Y., Wedzicha, J. A., Feder, G. S., & Griffiths, C. (2007) · Respiratory Research · doi:10.1186/1465-9921-8-93 · Cited by 79
Rossios, C., To, Y., To, M., Ito, M., Barnes, P. J., Adcock, I. M., Johnson, M. W., & Ito, K. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.08.022 · Cited by 76
Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
The TORCH investigators, Jones, P., Anderson, J. A., Calverley, P. M. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., Yates, J., Vestbo, J., & Spencer, M. D. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-71 · Cited by 74
Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis
Schermer, T. R., Chavannes, N. H., Dekhuijzen, R. P. N., Wouters, E. F. �., Muris, J. W. M., Akkermans, R. L. C., van Schayck, O. C. P., & van Weel, C. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.003 · Cited by 73
Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness
Verhoeven, G. T. (2002) · Thorax · doi:10.1136/thorax.57.8.694 · Cited by 71
Inhaled Corticosteroids vs Placebo for Preventing COPD Exacerbations
Agarwal, R., Aggarwal, A. N., Gupta, D., et al. (2009) · CHEST Journal · doi:10.1378/chest.09-1305 · Cited by 68
Weir, D. C., Bale, G., Bright, P., & Burge, P. S. (1999) · Clinical & Experimental Allergy · doi:10.1046/j.1365-2222.1999.00021.x · Cited by 67
Briggs, A. H., Glick, H. A., Lozano‐Ortega, G., Spencer, M., Calverley, P. M. A., Jones, P. W., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00153108 · Cited by 66
Vestbo, J. (2005) · Thorax · doi:10.1136/thx.2004.025411 · Cited by 61
Senderovitz, T., Vestbo, J., Frandsen, J., Maltbæk, N., Nørgaard, M., Nielsen, C., Kampmann, J. P., & The Danish Society of Respiratory Medicine (1999) · Respiratory Medicine · doi:10.1016/s0954-6111(99)90038-0 · Cited by 59
Partridge, M. R., Schuermann, W., Beckman, O., Persson, T., & Polanowski, T. (2009) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465809344870 · Cited by 55
Blais, L., Forget, A., & Ramachandran, S. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.022 · Cited by 53
Agustí, A. G. N., de Teresa, L., Backer, W. D., Zvarich, M. T., Locantore, N., Barnes, N. C., Bourbeau, J., & Crim, C. C. (2013) · European Respiratory Journal · doi:10.1183/09031936.00054213 · Cited by 52
Briggs, A. H., Lozano‐Ortega, G., Spencer, S., Bale, G., Spencer, M. D., & Burge, P. S. (2006) · Value in Health · doi:10.1111/j.1524-4733.2006.00106.x · Cited by 30
Fukuchi, Y., Samoro, R., Fassakhov, R. S., Taniguchi, H., Ekelund, J., Carlsson, L., & Ichinose, M. (2013) · Respirology · doi:10.1111/resp.12090 · Cited by 29
Bale, G., Martínez‐Camblor, P., Burge, P. S., & Soriano, J. B. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.04.001 · Cited by 27
Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association
Singanayagam, A., Chalmers, J. D., & Hill, A. T. (2010) · QJM · doi:10.1093/qjmed/hcq023 · Cited by 27
Methods for therapeutic trials in COPD: lessons from the TORCH trial
Keene, O. N., Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., & Jones, P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00122608 · Cited by 26
DiSantostefano, R. L., Li, H., Rubin, D. B., & Stempel, D. A. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001838 · Cited by 26
Inhaled corticosteroids in COPD: quantifying risks and benefits
Cates, C. J. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202959 · Cited by 23
Löfdahl, C. G., Postma, D. S., Laitinen, L. A., Ohlsson, S. V., Pauwels, R., & Pride, N. B. (1998) · Respiratory Medicine · doi:10.1016/s0954-6111(98)90293-1 · Cited by 22
Chavannes, N. H., Schermer, T. R., Wouters, E. F. �., et al. (2009) · International Journal of COPD · doi:10.2147/copd.s8196 · Cited by 17
Cited by
Pulmonary rehabilitation for chronic obstructive pulmonary disease
McCarthy, B., Casey, D., Devane, D., Murphy, K., Murphy, E., & Lacasse, Y. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003793.pub3 · Cited by 2,643
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Rabe, K. F., Martinez, F. J., Ferguson, G. T., Wang, C., Singh, D., Wedzicha, J. A., Trivedi, R., St. Rose, E., Ballal, S., McLaren, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916046 · Cited by 690
Vestbo, J., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Crim, C., Martinez, F., Yates, J., & Newby, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30069-1 · Cited by 483
Clinical Pharmacology of Corticosteroids
Williams, D. M. (2018) · Respiratory Care · doi:10.4187/respcare.06314 · Cited by 460
Singh, D., Papi, A., Corradi, M., Pavlišová, I., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., & Vestbo, J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31354-x · Cited by 425
Metadata
- Authors
- Kew, K. M., & Seniukovich, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-03-10
- Volume
- 2014
- Issue
- 12
- Pages
- CD010115-CD010115
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2139192099
- Cited by
- 398
- References
- 104
- FWCI
- 38.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.